Yf-Vax Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Yf-Vax market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historic period can be attributed to the rise in global travel to areas affected by yellow fever and heightened awareness about the importance of preventing the disease. Additionally, there has been an increasing recognition of the role immunization plays in controlling yellow fever transmission.

The projected growth in the forecast period is driven by the rising demand for vaccinations in emerging markets, improvements in vaccine distribution channels, and the expansion of government-sponsored vaccination programs. Further advancements in vaccine distribution infrastructure and enhancements in vaccine formulations and availability will also contribute to growth. Key trends expected in the forecast period include product approvals, strategic partnerships, and ongoing developments in yellow fever vaccines.

The growing awareness of vector-borne diseases is expected to drive the expansion of the yf-vax market. Vector-borne diseases are infectious conditions spread to humans and animals through the bites of infected arthropods, such as mosquitoes, ticks, and fleas, which carry pathogens like viruses, bacteria, or parasites, leading to illnesses such as malaria, dengue, and Lyme disease. The rise in the prevalence of these diseases is attributed to factors like climate change, urbanization, increased global travel, and the expansion of mosquito populations, resulting in more frequent outbreaks. YF-Vax helps prevent yellow fever, a vector-borne disease, by stimulating the immune system to produce antibodies that provide long-lasting protection against the virus spread by infected mosquitoes. For example, in March 2024, the World Organization for Animal Health reported 2,422 outbreaks of vector-borne diseases across 28 countries from 2023 to March 2024, with Europe experiencing 697 outbreaks. As awareness of vector-borne diseases rises, it is contributing to the growth of the yf-vax market.

The increasing healthcare spending is expected to drive the yf-vax market's growth. Factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, and higher demand for healthcare services are contributing to rising healthcare expenditures. YF-VAX helps reduce healthcare costs by preventing severe yellow fever infections, which lowers expenses associated with treatment, hospitalizations, and outbreak management. For instance, in May 2024, the Office for National Statistics in the UK reported that healthcare spending grew by 5.6% from 2022 to 2023, compared to 0.9% growth in 2022. The UK’s healthcare expenditure amounted to $317.63 billion (£292 billion) in 2023. Consequently, the rise in healthcare spending is fostering the growth of the yf-vax market.

A notable trend in the yf-vax market is the adoption of strategic partnerships to enhance technological integration and expand market presence. Strategic partnerships involve collaborations between organizations, where they combine resources, expertise, and efforts to achieve mutual goals. For example, in March 2022, the International Finance Corporation (IFC), a US-based financial services company, partnered with Institut Pasteur de Dakar (IPD), a Senegal-based yellow fever vaccine manufacturer, to establish a vaccine manufacturing facility in Senegal. The $222 million project, financed through a combination of public, private, and grant funding, will significantly boost IPD's production capacity, initially focusing on COVID-19 vaccines, with plans to expand to other vaccines. Once fully operational, the facility aims to produce up to 300 million doses annually for Africa.

Major players operating in the yf-vax market are Sanofi S.A.

North America was the largest region in the yf-vax market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in yf-vax report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the yf-vax market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

YF-Vax is a live-attenuated vaccine developed to offer long-term protection against yellow fever, a serious viral illness transmitted by infected mosquitoes. It is frequently recommended for travelers and residents in areas where the disease is endemic.

The primary forms of YF-Vax include live-attenuated vaccines and fractional dose vaccines. Live-attenuated vaccines consist of weakened, yet live, versions of the virus or bacteria responsible for the disease. The disease can be transmitted through different types: sylvatic yellow fever, intermediate yellow fever, and urban yellow fever. These vaccines are available through multiple distribution channels, such as hospitals, retail pharmacies, and government health programs, and are used by various age groups, including adults, the elderly, and children.

The Yf-Vax market research report is one of a series of new reports that provides Yf-Vax market statistics, including Yf-Vax industry global market size, regional shares, competitors with a Yf-Vax market share, detailed Yf-Vax market segments, market trends, and opportunities, and any further data you may need to thrive in the Yf-Vax industry. This Yf-Vax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The yf-vax market consists of sales of vaccine syringes, pre-filled injection devices, and immunization kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.